News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Winston Pharmaceuticals, Inc. (WPHM.OB) Announces Positive Results of Phase II Clinical Trial of Dolorac(R) Nasal Solution



11/22/2010 11:37:01 AM

VERNON HILLS, Ill.--(BUSINESS WIRE)--Winston Pharmaceuticals, Inc. (“Winston”), a specialty pharmaceutical company focused on developing and commercializing novel pain management therapies, announced the results of its Phase II study on its patented Dolorac® Nasal Solution (doxepin 0.4%) for prophylaxis of chronic migraine (“CM”) at the Lazard Capital Markets 7th Annual Healthcare Conference in New York.

Read at BioSpace.com


comments powered by Disqus
   
Migraine

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES